Rein Therapeutics, Inc.

Name: Rein Therapeutics, Inc. standardized financial statements, quarterly
Creator: Listed

RNTXNasdaqCIK 1420565HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q2 FY2026

Operating income−$6.1m, Q2 FY2026

Net income−$6.4m, Q2 FY2026

Rein Therapeutics, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Research and development	$m	0.0	2.0	3.5	3.7	3.7	3.3	3.1	4.3	1.7	2.0	3.1	3.6
Operating income	$m	(2.0)	(7.3)	(7.2)	(9.0)	(6.1)	(42.8)	(5.6)	(6.9)	(5.5)	(32.7)	(5.2)	(6.1)
Income tax	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Net income	$m	(1.8)	(7.3)	(7.1)	(8.9)	(5.8)	(41.0)	(5.5)	(6.8)	(5.6)	(32.0)	(5.8)	(6.4)
Diluted EPS	$ per share	(0.40)	not reported	(0.86)	(0.45)	(0.27)	not reported	(0.25)	(0.28)	(0.21)	not reported	(0.19)	(0.10)
Basic EPS	$ per share	(0.40)	not reported	(0.86)	(0.45)	(0.27)	not reported	(0.25)	(0.28)	(0.21)	not reported	(0.19)	(0.10)

Balance sheet

Cash and equivalents$8.5m, Q2 FY2026

Shareholders' equity$55.2m, Q2 FY2026

Rein Therapeutics, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	12.1	17.3	12.0	21.9	17.7	12.9	7.4	5.7	4.0	3.2	4.4	8.5
Current assets	$m	12.8	18.3	12.8	23.2	18.7	13.7	8.3	6.6	5.2	4.3	5.5	41.5
Total assets	$m	12.8	106	99.2	109	104	62.2	57.6	57.5	53.7	24.2	26.3	66.0
Current liabilities	$m	1.6	4.4	4.5	4.9	5.7	5.7	6.0	7.7	5.7	6.2	13.6	9.7
Total liabilities	$m	1.6	7.7	7.9	8.4	9.0	7.8	7.7	9.5	7.5	7.2	14.7	10.8
Shareholders' equity	$m	11.2	98.3	91.3	101	95.2	54.4	49.9	48.0	46.2	16.9	11.6	55.2

Cash flow

Operating cash flow−$8.6m, Q2 FY2026

Rein Therapeutics, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(1.6)	(10.4)	(5.3)	(8.4)	(3.8)	(4.8)	(6.2)	(6.4)	(3.5)	(3.2)	(3.4)	(8.6)
Capital expenditure	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)67.08m, Q2 FY2026

Rein Therapeutics, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	4.5	4.5	4.5	4.5	8.3	19.9	21.7	21.9	24.2	26.4	30.4	67.1

Shares outstanding: 86.27m at Aug 12, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. Listed shows no prices and gives no investment advice.